Ten‐year clinical outcomes of biodegradable vs durable polymer new‐generation drug‐eluting stent in patients with coronary artery disease with and without diabetes mellitus

By Lenz T, Koch T, Joner M, et al
Published June 3, 2021

Key Takeaways

In the present study, the researchers sought to evaluate the 10‐year clinical outcome of new‐generation biodegradable polymer‐based sirolimus‐eluting stents (Yukon Choice PC) compared with permanent polymer‐based everolimus‐eluting stents (XIENCE) in patients with and without diabetes mellitus. Outcomes of patients with or without diabetes mellitus treated with drug‐eluting stents were compared in a prespecified subgroup analysis. The study included 1,951 patients (560 patients with and 1,391 patients without diabetes mellitus) who were randomly assigned to either Yukon Choice PC (n = 1,299) or Xience (n = 652). No significant difference was found between patients treated with Yukon Choice PC vs Xience, neither in the subgroup of patients with nor without diabetes mellitus. The clinical outcome of diabetic patients after percutaneous coronary intervention with various new-generation drug-eluting stents is significantly worse than that of patients without diabetes mellitus, with event rates steadily increasing out to 10 years.

Read the full article on Journal of the American Heart Association.

Share with emailShare to FacebookShare to LinkedInShare to Twitter